Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two upcoming scientific conferences. On August 11, John Hunter, PhD, Site Head & Vice President, Antibody Research & Development at Compugen USA, Inc., will present at the Immunotherapies and Vaccines Summit (ImVacs) being held from August 11-14, in Boston, MA.
Help employers find you! Check out all the jobs and post your resume.